Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information

NOTE 15 – SEGMENT INFORMATION

Information related to the Company’s reportable operating business segments is shown below. The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies.

The Company has identified the following business segments:

•     The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry and includes consolidated reporting of TI Services, and the consolidated reporting of the Company’s 50/50 joint venture with RadQual.

•     The Cobalt Products segment includes management of a cobalt irradiation contract, fabrication of cobalt capsules for teletherapy or irradiation devices, and recycling of expended cobalt sources.

•     The Radiochemical Products segment includes production and distribution of various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by the Company or are purchased in bulk from other producers and distributed by the Company in customized packages and chemical forms tailored to customer and market demands.  Iodine-131 is the predominant radiochemical sold in this segment and an abbreviated new Drug Application (aNDA) has been submitted to the U.S. FDA to market this as a generic drug product upon approval.

•     The Fluorine Products segment historically involved the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. During 2013, these testing activities were completed, and the pilot plant facility was closed.  The Company has developed or acquired all patent rights to these processes. Future work in this segment will involve license support and, as financing permits, further work related to the de-conversion facility.

•    The Radiological Services segment concerns a wide array of miscellaneous services that consists of gemstone processing and field services that include source installation, removal, and radiation device decommissioning.

The following presents certain segment information as of and for the years ended December 31, 2018 and 2017:

Sale of product		2018		2017 (as adjusted)
Radiochemical products	$	2,264,007	$	2,321,732
Cobalt products		2,041,579		507,904
Nuclear medicine standards		3,788,779		3,232,229
Radiological services		2,274,458		1,358,525
Fluorine products		-		-
Total segments		10,368,823		7,420,390
Corporate revenue		-		-
Total consolidated	$	10,368,823	$	7,420,390
Depreciation and amortization		2018		2017 (as adjusted)
Radiochemical products	$	27,015	$	8,015
Cobalt products		6,839		35,790
Nuclear medicine standards		66,272		27,932
Radiological services		44,152		49,854
Fluorine products		113,666		113,691
Total segments		257,944		235,282
Corporate depreciation and amortization		9,775		6,154
Total consolidated	$	267,719	$	241,436
Segment income (loss)		2018		2017 (as adjusted)
Radiochemical products	$	289,773	$	402,158
Cobalt products		523,795		229,954
Nuclear medicine standards		675,367		627,832
Radiological services		1,122,604		545,814
Fluorine products		(122,651)		(209,110)
Total segments		2,488,888		1,596,648
Corporate loss		(3,333,464)		(5,353,932)
Total consolidated	$	(844,576)	$	(3,757,284)
Expenditures for segment assets		2018		2017 (as adjusted)
Radiochemical products	$	62,130	$	40,863
Cobalt products		-		-
Nuclear medicine standards		22,630		2,940
Radiological services		-		13,277
Fluorine products		1,560		14,223
Total segments		86,320		71,303
Corporate purchases		-		38,812
Total consolidated	$	86,320	$	110,115
Segment assets		2018		2017 (as adjusted)
Radiochemical products	$	344,994	$	282,971
Cobalt products		2,611,939		1,813,356
Nuclear medicine standards		2,113,960		2,214,061
Radiological services		281,077		198,437
Fluorine products		5,590,053		5,702,159
Total segments		10,942,023		10,210,984
Corporate assets		2,048,053		1,794,310
Total consolidated	$	12,990,076	$	12,005,294